Signifier Medical Technologies Collaborates With Global Sleep Experts on Its Innovative Snoozeal® Device Clinical Trials

Signifier Medical Technologies today announced that it is partnering with twenty-seven Key Opinion Leaders in Sleep to test and build awareness around its Snoozeal® product in the lead up to its commercial launch. The company are innovators in the sleep-disordered breathing market

This research-focused initiative enhances Signifier Medical Technologies’ ability to fine-tune its revolutionary genioglossal muscle-neurostimulation technology and ensure that it meets the needs of patients around the world. It will also help refine internal commercial processes and ensure a seamless experience for future patients.

Key Opinion Leaders include top-tier physicians in key sleep therapeutic areas, including pulmonologists, cardiologists, neurologists and ear, nose and throat (ENT) specialists from leading health academies and institutions in North America, Europe and Australia. Signifier Medical Technologies is working with these medical professionals to build a large acceptance of the efficacy and the safety of this new technology and create a large multi-center clinical dataset that will further expand on the recent trials in Europe and United States.

Professor Atul Malhotra, Chief Investigator at the University of CaliforniaSan Diego for Snoozeal® mentioned the enthusiasm for having a new technology in this space. “I have been involved with the Snoozeal® device and have been doing ongoing research on this treatment. I am optimistic that this treatment will be an important treatment approach for patients with snoring and with mild sleep apnoea.”

“I have been very surprised by this device. The feedback and adherence from patients have been excellent, reporting an improvement in their snoring. The integration between the app and the device work is smooth, easy, and intuitive.” Dr. Peter M Baptista, MD, Ph.D. mentioned after using the device in some of his patients in Clínica Universidad de Navarra.

“We are pleased to work with professionals from some of the world’s top medical and academic institutions to revolutionize the sleep market,” said Prof Anshul Sama, co-founder, and CMO of Signifier Medical Technologies. “Our work together could impact the respiratory health of hundreds of millions of people and incorporates the latest and most innovative research in the field.”

These latest collaborations are an important step towards the global commercialization of Signifier Medical Technologies’ Snoozeal® product; currently commercially tested in the UK market.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Led by researchers at NYU Grossman School of Medicine, the study results add to evidence that neighboring brain regions, the inferior frontal gyrus and the motor cortex, play an important role in such planning before words are said aloud. Both are part of the folded top layers of the brain, or cerebral cortex, which has long been known to control the muscle (motor) movements in the throat and mouth needed to produce speech. Less clear until now was how closely these regions determine the mix of sounds and words people want to say aloud, the authors report.
PolarisAR describes STELLAR Knee as a mixed-reality surgical navigation platform that guides TKA procedures by displaying measured and computed data overlaid directly in a 3D environment. The mixed-reality system acts as a spatial computer, creating continuous data exchange between the surgeon and the software to help enhance surgical decision-making while simplifying operating room workflow.
This February, the first enrolled patient underwent open surgical aortic arch reconstruction at the University of Pennsylvania, Presbyterian Medical Center, Philadelphia, PA.  During the surgery, the Duett Vascular Graft System was successfully deployed to connect the native left common carotid artery to the surgical graft.
"Our ultra low insertion loss Athermal AWG Multiplexers along with temperature-hardened low-drift AAWG specifically designed for the industrial temperature applications will be marketed aggressively through partnership companies in the East Asia and EU regions after its success in the North America," says Dr. Donald Yu, CMO of POINTek, who runs global marketing operations from Los Angeles, California.
AUX-001 is an innovative, once-daily, extended-release formulation of Nicorandil. For decades, immediate-release, twice daily Nicorandil has been a cornerstone treatment for chronic angina symptoms outside the US, distinguished by its dual mechanism of action that targets both the micro- and macrovascular coronary artery flow bed, and providing sustained angina symptom relief without the common issue of tachyphylaxis seen with other anti-anginal vasodilators like long-acting nitrates. AUX-001 offers efficacy comparable to conventional anti-anginal medications such as beta-blockers, calcium channel blockers, and long-acting nitrates while also potentially enhancing control of the underlying coronary disease and reducing angina related hospitalizations.

By using this website you agree to accept Medical Device News Magazine Privacy Policy